SureTrader Advertisement Advertisement
Home > Boards > US OTC > Medical - Drugs >

Entest BioMedical Inc. (ENTB)

Add ENTB Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator gotinearly, 1-eye-jack, ronrooster, sizzleweed
Search This Board:
Last Post: 11/25/2015 8:07:15 AM - Followers: 465 - Board type: Free - Posts Today: 1






Company Information:                                                      
4700 Spring Street, Suite 304
La Mesa, Calif. 91942
Telephone: 619-644-3344
Fax: 619-330-2328

Web site:


CIK 0001449447

ImenVax (TM)

Immuno-Therapeutic Cancer Treatment for Canines


In the encapsulated ImenVax™ device, a "cocktail" of integral immuno-catalysts are enclosed. From this ImenVax™ device immuno-catalysts are released which activate the patient's immune cell. These immune cells carry on their normal course of activity by entering the lymph nodes and cause T-Cell adaptation. These T-Cells are what attack and kill the tumor. (Figure 1)

Entest BioMedical Inc. (OTCQB: ENTB)is a majority owned subsidiary of Bio-Matrix Scientific Group Inc (OTCQB: BMSN). The Company is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), cancer immuno-therapies, testing procedures for diabetes and stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation).

Currently, Entest is focused on research and development in areas of COPD and Immuno-Therapeutic Cancer Vaccines. The Company sees applications for its patent pending technologies in both human and animal venues.

Immuno-therapeutic treatment of cancer - The patent pending Entest application involves perfecting the use of cell lines for sustained release of immunologically relevant cytokines for maximum anti-tumor immune responses in treating cancer. The treatment process itself will utilize an implantable encapsulation device as the vaccine delivery system and the initial focus will be treatment of cancer in canines. This canine cancer treatment may also provide clinical support for expansion into human cancer treatment.

Chronic Obstructive Pulmonary Disease -There is currently no cure for COPD and therapy is limited to management of the condition and its symptoms. Over the next 5 years, it is estimated that over $170 billion will be spent on treating COPD in the United States. Entest believes its COPD treatment, which utilizes patent pending adult stem cell therapy coupled with photoceutical device enhancement, has the potential to reverse COPD related lung damage as well as alleviate symptoms.

Entest BioMedical was founded for the purpose of providing excellence in biotechnology research (including adult stem cell regenerative treatment). Our objectives go beyond developing single products and procedures. Our mission is to discover and develop new procedures, treatments and medical devices that improve the quality of life. Our efforts revolve around a business focus of developing leading research and technology. Ongoing R&D is paramount to us in developing products and procedures with purpose, products and services that serve the present and help shape the future.



David R. Koos, PhD, DBA - Chairman and CEO, Secretary, Acting CFO
Feng Lin, MD, PhD - Director of Research
Marilyn Panahi - Director of Quality Assurance

 Recent News!

June 1, 2015




  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
ENTB News: Current Report Filing (8-k) 10/02/2015 03:06:12 PM
ENTB News: Current Report Filing (8-k) 07/31/2015 03:24:13 PM
ENTB News: Quarterly Report (10-q) 07/09/2015 05:21:46 PM
ENTB News: Current Report Filing (8-k) 06/26/2015 06:15:40 AM
#37380  Sticky Note Entest BioMedical's Zander Therapeutics Unit Files Patent Application gotinearly 08/11/15 09:52:49 AM
#37641   Not looking good here Lockman 11/22/15 06:31:36 PM
#37640   Almost 50% LOSE since the r/s. It was, mathematically, angelicsatan666 11/21/15 09:51:17 AM
#37639   Lets see now if Lander will be more JokersWild12 11/20/15 06:27:19 PM
#37638   A big room with an echo jeffshir 11/19/15 08:24:38 PM
#37637   Exactly what are you looking at? ctvette2003 11/19/15 07:44:59 PM
#37636   looking good here jeffshir 11/19/15 09:50:42 AM
#37633   ~ ENTB = This Stock went Silent... 1-eye-jack 11/12/15 08:35:45 PM
#37632   preach brother, and amen! jhenmal 11/11/15 01:47:41 PM
#37631   Contacting the SEC concerning the same activity Brakeman 11/11/15 09:30:53 AM
#37630   FDA Launches Orange Book Mobile Application jeffshir 11/09/15 02:38:37 PM
#37629   it's truly a d doggy pile here jhenmal 11/06/15 10:45:52 PM
#37628   This is going all the way back to BigPennyHunter 11/06/15 02:17:38 PM
#37627   I know! On and on and on and Brakeman 11/06/15 07:37:36 AM
#37626   expect zeros at two fifty nine pm like jhenmal 11/05/15 11:48:29 AM
#37625   On and on and on and on and JokersWild12 11/05/15 10:40:02 AM
#37624   Regen BioPharma Files Patent Application on Personalized Checkpoint ronrooster 11/04/15 10:58:43 AM
#37623   my guess is you're barking up the wrong jhenmal 11/03/15 07:01:20 PM
#37622   Man. I've had a buy in all day. NoQuarter 11/03/15 06:38:50 PM
#37621   The new hedge fund guy is going to Brakeman 11/03/15 12:53:12 PM
#37620   looks like the entire volume consisted of jhenmal 11/02/15 09:37:47 PM
#37619   Wow huge volume all day at .16, then gotinearly 11/02/15 03:42:19 PM
#37618   30k share block sold again hmmm prof81 11/02/15 11:27:24 AM
#37617   doubtful, IF there is a dividend, it will gotinearly 10/28/15 04:21:10 PM
#37616   Wild projection.IMO What is the possibility KOOS utilizes ronrooster 10/28/15 03:54:23 PM
#37615   I think this company forgot about us. oneflew12 10/27/15 09:23:55 AM
#37614   The Naked Shorters ? Brakeman 10/21/15 12:25:03 PM
#37613   When you lock your prices all it does prof81 10/21/15 10:16:07 AM
#37612   how come entb doe not trade anymore? vegasdrummer 10/19/15 10:46:20 AM
#37609   ~ ENTB = Yup... 1-eye-jack 10/15/15 10:30:53 PM
#37608   Unpacking the inefficiencies,Intensions, and unclear Ethics of the Brakeman 10/15/15 12:33:13 PM
#37607   I guess were all sleeping at this moment oneflew12 10/15/15 09:23:26 AM
#37606   New President JokersWild12 10/13/15 03:17:10 PM
#37605   That's what can be expected when Koos puts JokersWild12 10/09/15 02:24:56 PM
#37604   This sucks not even a bone. oneflew12 10/09/15 02:17:49 PM
#37603   news in reality is no news just jhenmal 10/08/15 08:26:34 PM
#37602   What a FLOP. I've never seen a CEO JokersWild12 10/08/15 10:56:09 AM
#37601   This is what happens when things don't look Brakeman 10/06/15 10:21:24 AM
#37600   Prof81, I love the way you dream and ctvette2003 10/06/15 09:40:39 AM
#37599   Holy crap!!!! Wait till everyone hears what's going prof81 10/06/15 09:21:41 AM
#37598   Get out now and buy back in at Lockman 10/05/15 12:57:52 PM
#37597   Remember that when the R/S was completed, there bucks2pennies 10/03/15 04:15:36 PM
#37596   ENTB. "On September 28, 2015 Zander Therapeutics, bucks2pennies 10/02/15 04:04:35 PM
#37595   Thats a Great Story ! He haw, but Brakeman 10/02/15 12:28:35 PM
#37594   Bucks,good realistic summary.I agree with you that our ronrooster 10/02/15 12:22:43 PM
#37593   ENTB. A little forethought. This is bucks2pennies 10/02/15 11:39:23 AM
#37592   At least this week no PR's from the JokersWild12 10/02/15 10:16:57 AM
#37590   I didnt know until this group of Koos JokersWild12 10/01/15 11:26:28 AM
#37589   Crony is the correct spelling, and I agree.:( Brakeman 09/30/15 08:24:52 AM
#37588   Who are the cronies in this post? gotinearly 09/29/15 04:36:59 PM
#37586   Indeed! Brakeman 09/29/15 01:45:21 PM